These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 34248854)

  • 1. Circulating Fascin 1 as a Promising Prognostic Marker in Adrenocortical Cancer.
    Cantini G; Fei L; Canu L; De Filpo G; Ercolino T; Nesi G; Mannelli M; Luconi M
    Front Endocrinol (Lausanne); 2021; 12():698862. PubMed ID: 34248854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fascin-1 Is a Novel Prognostic Biomarker Associated With Tumor Invasiveness in Adrenocortical Carcinoma.
    Poli G; Ruggiero C; Cantini G; Canu L; Baroni G; Armignacco R; Jouinot A; Santi R; Ercolino T; Ragazzon B; Assie G; Mannelli M; Nesi G; Lalli E; Luconi M
    J Clin Endocrinol Metab; 2019 May; 104(5):1712-1724. PubMed ID: 30476173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of FSCN1 and FOXM1 are associated with poor prognosis of adrenocortical carcinoma patients.
    Liang J; Liu Z; Wei X; Zhou L; Tang Y; Zhou C; Wu K; Zhang F; Zhang F; Lu Y; Zhu Y
    BMC Cancer; 2019 Nov; 19(1):1165. PubMed ID: 31783819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum inhibin pro-αC is a tumor marker for adrenocortical carcinomas.
    Hofland J; Feelders RA; van der Wal R; Kerstens MN; Haak HR; de Herder WW; de Jong FH
    Eur J Endocrinol; 2012 Feb; 166(2):281-9. PubMed ID: 22127493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FSCN1 as a new druggable target in adrenocortical carcinoma.
    Ruggiero C; Tamburello M; Rossini E; Zini S; Durand N; Cantini G; Cioppi F; Hantel C; Kiseljak-Vassiliades K; Wierman ME; Landwehr LS; Weigand I; Kurlbaum M; Zizioli D; Turtoi A; Yang S; Berruti A; Luconi M; Sigala S; Lalli E
    Int J Cancer; 2023 Jul; 153(1):210-223. PubMed ID: 36971100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of IGF and IGFBP as prognostic serum biomarkers for adrenocortical carcinoma.
    Patel D; Ellis R; Howard B; Boufraqech M; Gara SK; Zhang L; Quezado MM; Nilubol N; Kebebew E
    Ann Surg Oncol; 2014 Oct; 21(11):3541-7. PubMed ID: 24833102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The FSCN1 gene rs2966447 variant is associated with increased serum fascin-1 levels and breast cancer susceptibility.
    Abdullah AR; Gamal El-Din AM; Ismail Y; El-Husseiny AA
    Gene; 2024 Nov; 927():148743. PubMed ID: 38964493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Future directions in the diagnosis and medical treatment of adrenocortical carcinoma.
    Creemers SG; Hofland LJ; Korpershoek E; Franssen GJ; van Kemenade FJ; de Herder WW; Feelders RA
    Endocr Relat Cancer; 2016 Jan; 23(1):R43-69. PubMed ID: 26475053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence.
    Calabrese A; Basile V; Puglisi S; Perotti P; Pia A; Saba L; Berchialla P; Porpiglia F; Veltri A; Volante M; Reimondo G; Berruti A; Terzolo M
    Eur J Endocrinol; 2019 Jun; 180(6):387-396. PubMed ID: 30991359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer.
    Csizmarik A; Nagy N; Keresztes D; Váradi M; Bracht T; Sitek B; Witzke K; Puhr M; Tornyi I; Lázár J; Takács L; Kramer G; Sevcenco S; Maj-Hes A; Hadaschik B; Nyirády P; Szarvas T
    Prostate Cancer Prostatic Dis; 2024 Sep; 27(3):451-456. PubMed ID: 37634036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors.
    Fassnacht M; Dekkers OM; Else T; Baudin E; Berruti A; de Krijger R; Haak HR; Mihai R; Assie G; Terzolo M
    Eur J Endocrinol; 2018 Oct; 179(4):G1-G46. PubMed ID: 30299884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophil-Lymphocyte Ratio as a Prognostic Marker in Adrenocortical Carcinoma.
    Solak M; Kraljević I; Zibar Tomšić K; Kaštelan M; Kakarigi L; Kaštelan D;
    Endocr Res; 2021; 46(2):74-79. PubMed ID: 33416409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Role of Ki-67 in Adrenocortical Carcinoma After Primary Resection: A Retrospective Mono-Institutional Study.
    Zhang F; Zhang F; Liu Z; Wu K; Zhu Y; Lu Y
    Adv Ther; 2019 Oct; 36(10):2756-2768. PubMed ID: 31471770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological and Prognostic Characteristics of CD276 (B7-H3) Expression in Adrenocortical Carcinoma.
    Liang J; Liu Z; Pei T; Xiao Y; Zhou L; Tang Y; Zhou C; Wu K; Zhang F; Zhang F; Yin X; Chen N; Wei X; Lu Y; Zhu Y
    Dis Markers; 2020; 2020():5354825. PubMed ID: 31998416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of sex and functional status on the value of serum steroid profiling in discriminating adrenocortical carcinoma from adrenocortical adenoma.
    Weng Y; Tang JY; Zhang XY; Lin DZ; Guo Y; Liang Y; Wang L; Zhou J; Yan L; Lin TX; Zhang SL
    Front Endocrinol (Lausanne); 2024; 15():1435102. PubMed ID: 39359414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma.
    Sbiera S; Sbiera I; Ruggiero C; Doghman-Bouguerra M; Korpershoek E; de Krijger RR; Ettaieb H; Haak H; Volante M; Papotti M; Reimondo G; Terzolo M; Luconi M; Nesi G; Mannelli M; Libé R; Ragazzon B; Assié G; Bertherat J; Altieri B; Fadda G; Rogowski-Lehmann N; Reincke M; Beuschlein F; Fassnacht M; Lalli E
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3491-3498. PubMed ID: 28911143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between preoperative serum albumin and prognosis in patients with adrenocortical carcinoma after primary resection: a retrospective study.
    Zhang F; Liu Z; Liang J; Liu S; Wu K; Zhang F; Zhou C; Lu Y; Zhu Y; Wang X
    BMC Cancer; 2021 Aug; 21(1):961. PubMed ID: 34445989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical significance of FSCN1 in non-small cell lung cancer.
    Luo A; Yin Y; Li X; Xu H; Mei Q; Feng D
    Biomed Pharmacother; 2015 Jul; 73():75-9. PubMed ID: 26211585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fascin-1 expression as stratification marker in borderline epithelial tumours of the ovary.
    El-Balat A; Arsenic R; Sänger N; Karn T; Becker S; Holtrich U; Engels K
    J Clin Pathol; 2016 Feb; 69(2):142-8. PubMed ID: 26362828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients.
    Chabre O; Libé R; Assie G; Barreau O; Bertherat J; Bertagna X; Feige JJ; Cherradi N
    Endocr Relat Cancer; 2013 Aug; 20(4):579-94. PubMed ID: 23756429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.